Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep 5;20(18):4367.
doi: 10.3390/ijms20184367.

Animal Models of Inflammation for Screening of Anti-inflammatory Drugs: Implications for the Discovery and Development of Phytopharmaceuticals

Kalpesh R Patil  1 , Umesh B Mahajan  2 , Banappa S Unger  3 , Sameer N Goyal  4 , Sateesh Belemkar  5 , Sanjay J Surana  2 , Shreesh Ojha  6 , Chandragouda R Patil  7
Affiliations
Review

Animal Models of Inflammation for Screening of Anti-inflammatory Drugs: Implications for the Discovery and Development of Phytopharmaceuticals

Kalpesh R Patil et al. Int J Mol Sci. .

Abstract

Inflammation is one of the common events in the majority of acute as well as chronic debilitating diseases and represent a chief cause of morbidity in today's era of modern lifestyle. If unchecked, inflammation leads to development of rheumatoid arthritis, diabetes, cancer, Alzheimer's disease, and atherosclerosis along with pulmonary, autoimmune and cardiovascular diseases. Inflammation involves a complex network of many mediators, a variety of cells, and execution of multiple pathways. Current therapy for inflammatory diseases is limited to the steroidal and non-steroidal anti-inflammatory agents. The chronic use of these drugs is reported to cause severe adverse effects like gastrointestinal, cardiovascular, and renal abnormalities. There is a massive need to explore new anti-inflammatory agents with selective action and lesser toxicity. Plants and isolated phytoconstituents are promising and interesting sources of new anti-inflammatories. However, drug development from natural sources has been linked with hurdles like the complex nature of extracts, difficulties in isolation of pure phytoconstituents, and the yield of isolated compounds in minute quantities that is insufficient for subsequent lead development. Although various in-vivo and in-vitro models for anti-inflammatory drug development are available, judicious selection of appropriate animal models is a vital step in the early phase of drug development. Systematic evaluation of phytoconstituents can facilitate the identification and development of potential anti-inflammatory leads from natural sources. The present review describes various techniques of anti-inflammatory drug screening with its advantages and limitations, elaboration on biological targets of phytoconstituents in inflammation and biomarkers for the prediction of adverse effects of anti-inflammatory drugs. The systematic approach proposed through present article for anti-inflammatory drug screening can rationalize the identification of novel phytoconstituents at the initial stage of drug screening programs.

Keywords: animal models; anti-inflammatory; biomarkers; drug discovery; phytoconstituents.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(A) The inflammatory cascade; (B) The inflammatory cascade. The arrows in the figure represents process. The arrows in the figure represents process
Figure 1
Figure 1
(A) The inflammatory cascade; (B) The inflammatory cascade. The arrows in the figure represents process. The arrows in the figure represents process
Figure 2
Figure 2
Targets of phytoconstituents in inflammation. PLA2, Phospholipase A2; PLC, Phospholipase C; PKC, Protein kinase C; PAF, Platelet-activating factor; DAG, Diacylglycerol; IP3, Inositol triphosphate; COX, Cyclooxygenase; LOX, Lipoxygenase; PGs, Prostaglandins; LTs, Leukotrienes; MMP, Matrix metalloproteinase; HLE, Human leukocyte elastase; ILs, Interleukins, TNF-α, Tumor necrosis factor-alpha; NF-κB, Nuclear factor kappa beta; AP-1, Activator protein-1; MAPK, Mitogen-activated protein kinase; P38, P38 kinase; c-JUN, c-Jun N-terminal kinase; ERK, Extracellular signal-regulated kinase. The arrows in the figure represents the process and fork represents inhibition of target.
Figure 3
Figure 3
A systematic approach for preclinical evaluation of phytoconstituents.
Figure 4
Figure 4
Scheme for the preclinical evaluation of the acute anti-inflammatory activity.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dewanjee S., Dua T.K., Sahu R. Potential anti-inflammatory effect of Leea macrophylla Roxb. leaves: A wild edible plant. Food Chem. Toxicol. 2013;59:514–520. doi: 10.1016/j.fct.2013.06.038. - DOI - PubMed
    1. Kulkarni R.G., Achaiah G., Sastry G.N. Novel targets for antiinflammatory and antiarthritic agents. Curr. Pharm. Des. 2006;12:2437–2454. doi: 10.2174/138161206777698945. - DOI - PubMed
    1. Calixto J.B., Otuki M.F., Santos A.R.S. Anti-Inflammatory Compounds of Plant Origin. Part I. Action on Arachidonic Acid Pathway, Nitric Oxide and Nuclear Factor κ B (NF-κB) Planta Med. 2003;69:973–983. - PubMed
    1. Chung H.-J., Lee H.-S., Shin J.-S., Lee S.-H., Park B.-M., Youn Y.-S., Lee S.K. Modulation of acute and chronic inflammatory processes by a traditional medicine preparation GCSB-5 both in vitro and in vivo animal models. J. Ethnopharmacol. 2010;130:450–459. doi: 10.1016/j.jep.2010.05.020. - DOI - PubMed
    1. Simmons D.L. What makes a good anti-inflammatory drug target? Drug Discov. Today. 2006;11:210–219. doi: 10.1016/S1359-6446(05)03721-9. - DOI - PubMed

MeSH terms

LinkOut - more resources